SEC Form 4 · accession 0001171843-17-001686
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter P. Pfreundschuh
Officer — CFO
Period of report
Mar 20, 2017
Accepted (ET)
Mar 22, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $10.90 | Mar 20, 2017 | A | 150,000 | A | — | Mar 20, 2027 | Class A Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The option will vest over a four-year period, with 25% vesting on March 20, 2018 and the remaining 75% vesting in equal monthly increments over the three-year period thereafter.